Nemes Rush Group’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.64K Sell
12
-2
-14% -$742 ﹤0.01% 678
2026
Q1
$4.1K Buy
14
+10
+250% +$3.29K ﹤0.01% 657
2025
Q4
$1.4K Buy
+4
New +$1.35K ﹤0.01% 771
2025
Q3
Sell
-29
Closed -$11.3K 695
2025
Q2
$11.3K Hold
29
﹤0.01% 462
2025
Q1
$12.6K Sell
29
-10
-26% -$4.01K ﹤0.01% 445
2024
Q4
$14.4K Buy
39
+10
+34% +$4.18K ﹤0.01% 430
2024
Q3
$15K Hold
29
﹤0.01% 369
2024
Q2
$15.7K Hold
29
﹤0.01% 366
2024
Q1
$15K Sell
29
-18
-38% -$8.95K ﹤0.01% 406
2023
Q4
$22.2K Hold
47
﹤0.01% 338
2023
Q3
$20.5K Buy
47
+18
+62% +$8.16K ﹤0.01% 337
2023
Q2
$12.9K Buy
+29
New +$13.4K ﹤0.01% 402

Other funds holding ELV

Nemes Rush Group's ELV Position: Q2 2026 in Review

Nemes Rush Group reduced its Elevance Health (ELV) stake by 14% in Q2 2026, selling an estimated $742 and leaving 12 shares worth $4.64K. The position accounts for ﹤0.01% of the portfolio, ranked #678.

Nemes Rush Group first reported a position in ELV in Q2 2023 and has held it in 12 quarters since. The position peaked at $22.2K in Q4 2023. 1,608 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Nemes Rush Group held 12 shares of Elevance Health worth $4.64K as of Q2 2026.
  • Nemes Rush Group sold 2 Elevance Health shares in Q2 2026, an estimated $742.
  • Elevance Health made up ﹤0.01% of Nemes Rush Group's portfolio in Q2 2026, its #678 holding.
  • Nemes Rush Group first reported a position in Elevance Health in Q2 2023 and has held it in 12 quarters since.
  • Nemes Rush Group's Elevance Health position peaked at $22.2K in Q4 2023.
  • 1,608 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.